EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study

Yu-Tang Chang, Chou-Chen Chen, Shih-Ching Chang, Yu-Yao Chang iD, Bo-Wen Lin, Hong-Hwa Chen, Yao-Yu Hsieh iD, Hung-Chih Hsu, Meng-Che Hsieh, Feng-Che Kuan, Chih-Chien Wu, Wei-Chen Lu und 6 weitere

Nutrients · 2023

DOI: 10.3390/nu15132971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Yu-Tang Chang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck (Germany), Ministry of Science and Technology, Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malnutrition is a common problem in patients with metastatic colorectal cancer (mCRC) receiving targeted therapy plus chemotherapy, resulting in severe toxicity and decreased survival rates. This retrospective study employing propensity score matching (PSM) examined the efficacy and safety of a supplemental home parenteral nutrition (HPN) program for patients with RAS wild-type mCRC receiving cetuximab plus chemotherapy. This retrospective nationwide registry study included data from 14 medical centers/hospitals across Taiwan, and the data period ranged from November 2016 to December 2020. Patients with RAS wild-type mCRC receiving cetuximab plus chemotherapy as their first-line therapy were included and divided into HPN and non-HPN program groups. HPN was initiated based on patient-specific factors, such as baseline nutritional status, treatment-related toxicities, and comorbidities. Clinical outcomes were evaluated using response to therapy, duration of response (DoR), progression-free survival (PFS), and overall survival (OS). This study recruited 758 patients, of whom 110 and 648 were included in the HPN and non-HPN program groups, respectively. After 1:3 PSM, the data of 109 and 327 patients from the HPN and non-HPN program groups were analyzed, respectively. The HPN program group had a higher metastasectomy rate (33.9% vs. 20.2%, p = 0.005), and longer duration of treatment and DoR than the non-HPN program group (13.6 vs. 10.3 and 13.6 vs. 9.9 months, p = 0.001 and < 0.001, respectively). The HPN program group tended to have a longer median PFS (18.2 vs. 13.9 months, p = 0.102). Moreover, we noted a significant improvement in the median OS in the same group (53.4 vs. 34.6 months, p = 0.002). Supplemental HPN programs may be recommended for select patients with mCRC receiving targeted therapy plus chemotherapy to improve oncological outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsColonic NeoplasmsRectal NeoplasmsHumansCetuximabRetrospective StudiesPropensity ScoreParenteral NutritionAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

RAS wild-typecetuximabmetastatic colorectal cancersupplementary home parenteral nutrition

Substanzen

Cetuximab

Autor:innen und Institutionen

  • Division of Pediatric Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
  • Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
  • Department of Surgery, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
  • Division of Colon and Rectal Surgery, Department of Surgery, Veterans General Hospital, Taipei 11217, Taiwan.
  • Department of Colorectal Surgery, Changhua Christian Hospital, Changhua 50006, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 40227, Taiwan.

ORCID-Profile: Yu-Yao Chang, Yao-Yu Hsieh, Jaw-Yuan Wang

Förderung

  • Merck (Germany)
  • Ministry of Science and Technology
  • Ministry of Health and Welfare
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
  • Kaohsiung Medical University
  • Merck Ltd., Taipei, Taiwan, an affiliate of Merck KGaA, Darmstadt, Germany
  • health and welfare surcharge on tobacco products
  • Kaohsiung Medical University Hospital

Zitieren

APA

Chang, Y. T., Chen, C. C., Chang, S. C., Chang, Y. Y., Lin, B. W., Chen, H. H., Hsieh, Y. Y., Hsu, H. C., Hsieh, M. C., Kuan, F. C., Wu, C. C., Lu, W. C., Su, Y. L., Liang, Y. H., Chen, J. B., Huang, S. Y., Huang, C. W., & Wang, J. Y. (2023). Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study. Nutrients. https://doi.org/10.3390/nu15132971

Vancouver

Chang YT, Chen CC, Chang SC, Chang YY, Lin BW, Chen HH, et al. Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study. Nutrients. 2023. doi:10.3390/nu15132971

BibTeX
@article{Chang2023,
  author = {Chang, Yu-Tang and Chen, Chou-Chen and Chang, Shih-Ching and Chang, Yu-Yao and Lin, Bo-Wen and Chen, Hong-Hwa and Hsieh, Yao-Yu and Hsu, Hung-Chih and Hsieh, Meng-Che and Kuan, Feng-Che and Wu, Chih-Chien and Lu, Wei-Chen and Su, Yu-Li and Liang, Yi-Hsin and Chen, Joe-Bin and Huang, Shuan-Yuan and Huang, Ching-Wen and Wang, Jaw-Yuan},
  title = {Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15132971}
}
Kostenlos starten →